Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations

The gut microbiota has emerged as a key regulator of immune checkpoint inhibitor (ICI) efficacy. Therapeutic approaches aimed at manipulating the microbiota through targeted reconstitution to enhance cancer treatment outcomes have garnered considerable attention. A single live microbial biotherapeut...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-12, Vol.16 (1), p.47
Hauptverfasser:	Tomita, Yusuke, Sakata, Shinya, Imamura, Kosuke, Iyama, Shinji, Jodai, Takayuki, Saruwatari, Koichi, Hamada, Shohei, Akaike, Kimitaka, Anai, Moriyasu, Fukusima, Kazuaki, Takaki, Akira, Tsukamoto, Hirotake, Goto, Yoshihiko, Motozono, Chihiro, Sugata, Kenji, Satou, Yorifumi, Ueno, Takamasa, Ikeda, Tokunori, Sakagami, Takuro
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics Apoptosis Cancer therapies Cell death Chemotherapy Clinical outcomes Clostridium butyricum Dysbacteriosis Histology Immune checkpoint inhibitors Immunosuppressive agents Immunotherapy Intestinal microflora Lung cancer Medical records Metastases Metastasis Microbiota Non-small cell lung carcinoma Patients PD-L1 protein Proton pump inhibitors Small cell lung carcinoma Survival analysis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!